浏览全部资源
扫码关注微信
井冈山大学附属医院药剂科,江西 吉安 343000
Published:30 November 2023,
Received:05 May 2023,
Revised:25 October 2023,
扫 描 看 全 文
黄聪聪,彭靖,肖勋立等.CDK4/6抑制剂联合内分泌药物治疗HR阳性/HER2阴性乳腺癌疗效与安全性的Meta分析 Δ[J].中国药房,2023,34(22):2787-2792.
HUANG Congcong,PENG Jing,XIAO Xunli,et al.Meta-analysis of efficacy and safety of CDK4/6 inhibitor combined with endocrine in the treatment of HR+/HER2- breast cancer[J].ZHONGGUO YAOFANG,2023,34(22):2787-2792.
黄聪聪,彭靖,肖勋立等.CDK4/6抑制剂联合内分泌药物治疗HR阳性/HER2阴性乳腺癌疗效与安全性的Meta分析 Δ[J].中国药房,2023,34(22):2787-2792. DOI: 10.6039/j.issn.1001-0408.2023.22.18.
HUANG Congcong,PENG Jing,XIAO Xunli,et al.Meta-analysis of efficacy and safety of CDK4/6 inhibitor combined with endocrine in the treatment of HR+/HER2- breast cancer[J].ZHONGGUO YAOFANG,2023,34(22):2787-2792. DOI: 10.6039/j.issn.1001-0408.2023.22.18.
目的
2
评价4种周期蛋白依赖性激酶4/6(CDK4/6)抑制剂(达尔西利、阿贝西利、瑞波西利、哌柏西利)联合内分泌药物治疗激素受体(HR)阳性/人表皮生长因子受体2(HER2)阴性乳腺癌的疗效和安全性。
方法
2
计算机检索PubMed、the Cochrane Library、Web of Science、Embase、中国知网、万方数据、维普网,收集CDK4/6抑制剂联合内分泌药物(试验组)对比单用内分泌药物或联用安慰剂(对照组)的随机对照试验(RCT),检索时限为建库至2023年4月。筛选文献、数据提取和质量评价后,采用RevMan 5.4.1软件进行Meta分析。
结果
2
共纳入22篇文献,涉及15项RCT,合计18 574例患者。Meta分析结果显示,试验组患者的无进展生存期[HR=0.77,95%CI(0.74,0.79),
P
<0.000 01]、总生存期[HR=0.91,95%CI(0.87,0.94),
P
<0.000 01]、客观缓解率[OR=1.71,95%CI(1.51,1.93),
P
<0.000 01]、临床获益率[OR=1.73,95%CI(1.52,1.95),
P
<0.000 01]均显著优于对照组。试验组患者的≥3级不良反应[OR=10.28,95%CI(6.97,15.17),
P
<0.000 01]、中性粒细胞减少[OR=65.09,95%CI(36.43,116.31),
P
<0.000 01]、白细胞减少[OR=22.90,95%CI(15.40,34.04),
P
<0.000 01]、贫血[OR=5.71,95%CI(4.51,7.22),
P
<0.000 01]、腹泻[OR=3.00,95%CI(1.19,7.51),
P
<0.05]、恶心[OR=1.99,95%CI(1.52,2.60),
P
<0.000 01]发生率均显著高于对照组。
结论
2
CDK4/6抑制剂联合内分泌药物治疗HR阳性/HER2阴性乳腺癌的疗效显著,不良反应发生率较高,尤其是血液毒性反应。
OBJECTIVE
2
To evaluate the efficacy and safety of four cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (dalpicilib, abemacilib, ribocilib, palbocilib) combined with endocrine drugs in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR
+
/HER2
-
) breast cancer.
METHODS
2
Computer searches were conducted on PubMed, the Cochrane Library, Web of Science, Embase, CNKI, Wanfang data and VIP to collect randomized controlled trials (RCTs) about CDK4/6 inhibitors combined with endocrine drugs (trial group) versus endocrine drugs alone or combined with placebo (control group). The search period was from the establishment of the database to April 2023. After literature screening, data extraction and quality evaluation, a meta-analysis was conducted by using RevMan 5.4.1 software.
RESULTS
2
A total of 22 articles were included, involving 15 RCTs with a total of 18 574 patients. The meta-analysis results showed that the progression free survival [HR=0.77, 95%CI (0.74, 0.79),
P
<0.000 1], overall survival [HR=0.91, 95%CI (0.87, 0.94),
P
<0.000 01], objective response rate [OR=1.71, 95%CI (1.51, 1.93),
P
<0.000 01] and clinical benefit rate [OR=1.73, 95%CI (1.52, 1.95),
P
<0.000 01] of the trial group were significantly better than control group. The incidence of adverse drug reactions≥3 levels [OR=10.28,95%CI (6.97,15.17),
P
<0.000 01], neutropenia [OR=65.09, 95%CI (36.43, 116.31),
P
<0.000 01], leukopenia [OR=22.90, 95%CI (15.40, 34.04),
P
<0.000 01], anemia [OR=5.71, 95%CI (4.51, 7.22),
P
<0.000 01], diarrhea [OR=3.00, 95%CI (1.19, 7.51),
P
<0.05] and nausea [OR=1.99, 95%CI (1.52, 2.60),
P
<0.000 01] in the trial group was significantly higher than control group.
CONCLUSIONS
2
The combination of CDK4/6 inhibitors and endocrine drugs has a significant effect on HR
+
/HER2
-
breast cancer, with a high incidence of adverse reactions, especially hematotoxicity.
周期蛋白依赖性激酶4/6抑制剂内分泌药物激素受体阳性/人表皮生长因子受体2阴性乳腺癌疗效安全性
endocrine drugshormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancerefficacysafety
SUNG H,FERLAY J,SIEGEL R L,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
CARDOSO F,COSTA A,SENKUS E,et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer(ABC 3)[J]. Breast,2017,31:244-259.
HOWLADER N,ALTEKRUSE S F,LI C I,et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status[J]. J Natl Cancer Inst,2014,106(5):dju055.
MILANI A,GEUNA E,MITTICA G,et al. Overcoming endocrine resistance in metastatic breast cancer:current evidence and future directions[J]. World J Clin Oncol,2014,5(5):990-1001.
ALFAKEEH A,BREZDEN-MASLEY C. Overcoming endocrine resistance in hormone receptor-positive breast cancer[J]. Curr Oncol,2018,25(Suppl 1):S18-S27.
BILGIN B,SENDUR MAN,ŞENER DEDE D,et al. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer[J]. Curr Med Res Opin,2017,33(9):1559-1569.
LI J,FU F M,YU L W,et al. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive,human epidermal growth factor receptor-2 negative advanced breast cancer:a meta-analysis of randomized clinical trials[J]. Breast Cancer Res Treat,2020,180(1):21-32.
秦泽敏,易凡,刘满想,等. CDK4/6抑制剂联合内分泌治疗晚期乳腺癌有效性和安全性的Meta分析[J]. 中国循证医学杂志,2018,18(4):333-339.
QIN Z M,YI F,LIU M X,et al. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy for advanced breast cancer:a meta-analysis[J]. Chin J Evid Based Med,2018,18(4):333-339.
XU B H,ZHANG Q Y,ZHANG P,et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer:a randomized,phase 3 trial[J]. Nat Med,2021,27(11):1904-1909.
XU B,ZHANG Q Y,ZHANG P,et al. LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer(DAWNA-2):a phase Ⅲ trial[J]. Ann Oncol,2022,33:S1384-S1385.
SLEDGE G W, Jr,TOI M,NEVEN P,et al. MONARCH 2:abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy[J]. J Clin Oncol,2017,35(25):2875-2884.
SLEDGE G W, Jr,TOI M,NEVEN P,et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive,ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2:a randomized clinical trial[J]. JAMA Oncol,2020,6(1):116-124.
JOHNSTON S,MARTIN M,DI LEO A,et al. MONARCH 3 final PFS:a randomized study of abemaciclib as initial therapy for advanced breast cancer[J]. NPJ Breast Cancer,2019,5:5.
JOHNSTON S R D,TOI M,O’SHAUGHNESSY J,et al. Abemaciclib plus endocrine therapy for hormone receptor-positive,HER2-negative,node-positive,high-risk early breast cancer(monarchE):results from a preplanned interim analysis of a randomised,open-label,phase 3 trial[J]. Lancet Oncol,2023,24(1):77-90.
HORTOBAGYI G N,STEMMER S M,BURRIS H A,et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer[J]. N Engl J Med,2016,375(18):1738-1748.
HORTOBAGYI G N,STEMMER S M,BURRIS H A,et al. Overall survival with ribociclib plus letrozole in advanced breast cancer[J]. N Engl J Med,2022,386(10):942-950.
SLAMON D J,NEVEN P,CHIA S,et al. Phase Ⅲ randomized study of ribociclib and fulvestrant in hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:MONALEESA-3[J]. J Clin Oncol,2018,36(24):2465-2472.
SLAMON D J,NEVEN P,CHIA S,et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer in the phase Ⅲ rando-mized MONALEESA-3 trial:updated overall survival[J]. Ann Oncol,2021,32(8):1015-1024.
TRIPATHY D,IM S A,COLLEONI M,et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive,advanced breast cancer(MONALEESA-7):a randomised phase 3 trial[J]. Lancet Oncol,2018,19(7):904-915.
LU Y S,IM S A,COLLEONI M,et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7:a phase Ⅲ randomized clinical trial[J]. Clin Cancer Res,2022,28(5):851-859.
FINN R S,CROWN J P,LANG I,et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive,HER2-negative,advanced breast cancer(PALOMA-1/TRIO-18):a randomised phase 2 study[J]. Lancet Oncol,2015,16(1):25-35.
FINN R S,BOER K,BONDARENKO I,et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer(PALOMA-1,TRIO-18)[J]. Breast Cancer Res Treat,2020,183(2):419-428.
FINN R S,MARTIN M,RUGO H S,et al. Palbociclib and letrozole in advanced breast cancer[J]. N Engl J Med,2016,375(20):1925-1936.
RUGO H S,FINN R S,DIÉRAS V,et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up[J]. Breast Cancer Res Treat,2019,174(3):719-729.
TURNER N C,RO J,ANDRÉ F,et al. Palbociclib in hormone-receptor-positive advanced breast cancer[J]. N Engl J Med,2015,373(3):209-219.
CRISTOFANILLI M,RUGO H S,IM S A,et al. Overall survival with palbociclib and fulvestrant in women with HR+/HER2- ABC:updated exploratory analysis of PALOMA-3,a double-blind,phase Ⅲ randomized study[J]. Clin Cancer Res,2022,28(16):3433-3442.
XU B H,HU X C,LI W,et al. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer:primary results from PALOMA-4[J]. Eur J Cancer,2022,175:236-245.
LOIBL S,MARMÉ F,MARTIN M,et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the penelope-B trial[J]. J Clin Oncol,2021,39(14):1518-1530.
GNANT M,DUECK A C,FRANTAL S,et al. Adjuvant palbociclib for early breast cancer:the PALLAS trial results(ABCSG-42/AFT-05/BIG-14-03)[J]. J Clin Oncol,2022,40(3):282-293.
ALBANELL J,MARTÍNEZ M T,RAMOS M,et al. Randomized phase Ⅱ study of fulvestrant plus palbociclib or placebo in endocrine-sensitive,hormone receptor-positive/HER2-advanced breast cancer:GEICAM/2014-12(FLIPPER) [J]. Eur J Cancer,2022,161:26-37.
DUKELOW T,KISHAN D,KHASRAW M,et al. CDK4/6 inhibitors in breast cancer[J]. Anti Cancer Drugs,2015,26(8):797-806.
FINN R S,DERING J,CONKLIN D,et al. PD 0332991,a selective cyclin D kinase 4/6 inhibitor,preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro[J]. Breast Cancer Res,2009,11(5):R77.
ONESTI C E,JERUSALEM G. CDK4/6 inhibitors in breast cancer:differences in toxicity profiles and impact on agent choice: a systematic review and meta-analysis[J]. Expert Rev Anticancer Ther,2021,21(3):283-298.
LAURENTI E,FRELIN C,XIE S,et al. CDK6 levels regulate quiescence exit in human hematopoietic stem cells[J]. Cell Stem Cell,2015,16(3):302-313.
SPRING L M,WANDER S A,ANDRE F,et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer:past,present,and future[J]. Lancet,2020,395(10226):817-827.
0
Views
2
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution